SEC Form 5 · accession 0001214659-26-009589
Alzamend Neuro, Inc. · ALZN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William B. Horne
Director
Period of report
Apr 30, 2026
Accepted (ET)
Aug 4, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001677077
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $2.33 | Apr 17, 2026 | A | 60,000 | A | — | Nov 12, 2035 | Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Horne to purchase 60,000 shares of Common Stock. Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders. Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable. The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026.